I[ntroduction]{.smallcaps} {#sec1-1}
==========================

Transplant renal artery stenosis (TRAS) is one of the posttransplant vascular complications, its incidence varies from 1% to 25%.\[[@ref1][@ref2]\] TRAS reduces blood supply of renal allograft and may eventually lead to graft dysfunction or even graft failure.

The pathogenesis of TRAS is not fully elucidated. Hemodynamics is reported to influence atherogenesis, vascular remodeling, neointimal hyperplasia, and endothelial healing.\[[@ref3][@ref4][@ref5]\] Computational fluid dynamics (CFD) allows visual and accurate analysis of medical imaging data such as computed tomography angiography (CTA) and thus illustrates intrinsic hemodynamic mechanisms.\[[@ref6][@ref7][@ref8][@ref9][@ref10][@ref11]\] Although several CFD studies of native renal artery stenosis have been conducted, there are few studies about TRAS.\[[@ref12][@ref13]\] In addition, hemodynamics of transplant renal artery (TRA) might be quite different from that of native renal artery as TRA is anastomosed to iliac artery instead of abdominal aorta. Furthermore, most CFD studies use simplified models such as circular cross sections or semicircular sections,\[[@ref14]\] yet only few introduce patient-specific model which can provide more realistic and sensitive hemodynamic data based on individual patient\'s artery geometries.\[[@ref15][@ref16]\]

Endovascular interventions including balloon angioplasty and stents are introduced to preserve renal graft function once severe TRAS is diagnosed.\[[@ref17]\] Unfortunately, 10--50% of the treated TRAS occurred restenosis after endovascular interventions.\[[@ref18][@ref19]\] The intravascular hemodynamics change after stent treatment has not drawn much attention. Nevertheless, it has been shown that hemodynamic factors might contribute to restenosis after stent implantation in a vertebral artery stenosis model.\[[@ref9]\] Herein, we demonstrated the hemodynamic characteristics of TRAS and its alteration after stent treatment using a patient-specific CFD model, with normal renal graft arteries as control.

M[ethods]{.smallcaps} {#sec1-2}
=====================

Study patients {#sec2-1}
--------------

CTA data of kidney transplant recipients in Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University (China), from April 2013 to November 2014, were reviewed. The inclusion criteria were: (1) normal, stenotic, or stented TRA diagnosed with CTA; (2) TRA anastomosed to external iliac artery in an end-to-side manner; and (3) the degree of artery stenosis over 70% (defined as severe TRAS). The exclusion criteria were: (1) TRA anastomosed to internal iliac artery in an end-to-end manner; (2) stenosis of artery anastomosis; and (3) insufficient three-dimensional (3D)-CTA imaging quality for CFD analysis. This study was approved by the Institutional Ethics Committee of The First Affiliated Hospital of Sun Yat-Sen University (No. \[2016\]084) and was in compliance with the provisions of the current *Declaration of Helsinki* principles. Patient consent was not required because the study did not involve human participants, specimens, or tissues and did not intervene the diagnosis and treatment.

Fifteen patients with severe TRAS confirmed by CTA and digital subtraction angiography were included in the study, and three of them were then excluded from the study due to anastomosis stenosis (*n* = 2) or insufficient CTA resolution (*n* = 1). All the rest 12 patients received stent implantation, yet only six of them received secondary CTA examination several months after stenting. No restenosis was found. Normal renal graft artery without stenosis was confirmed in six patients who received CTA examination due to other clinical consideration. Thus, CTA data of 6 normal (control group), 12 stenotic (TRAS group), and 6 stented TRAs (stent group) were obtained for CFD analysis.

Transplant renal artery and stent deployment modeling {#sec2-2}
-----------------------------------------------------

All the 3D TRA geometries were obtained from CTA images. The commercial segmentation software Mimics 16.0 (Materialise Company, Leuven, Belgium) was used to transfer CTA images (DICOM format) into vessel-shaped 3D geometric data (STL format). Fast virtual stenting technique was used to simulate the process of stent implantation, which includes three steps: (1) isolation of parent vessel and creation of simplex mesh to fit the vessel best along its centerline using vessel-specific initialization; (2) expansion of simplex mesh to make the deployed simplex mesh a good apposition to the wall of the parent vessel; and (3) the stent mapped on the deployed simplex mesh and the wires swept into a 3D structure. Then, the deployed stent was incorporated into the specific geometry with ANSYS SpaceClaim software (ANSYS Company, Canonsburg, Pennsylvania, USA). ANSYS 16.0 software (ANSYS Company, Canonsburg, Pennsylvania, USA) was used to generate a computational grid consisting of approximately 0.03--0.07 million, 0.1--0.3 million, and 1.5--2.8 million tetrahedral elements in the merged normal, stenotic, and stented geometry, respectively. Steady-state CFD analysis was carried out with the finite volume code ANSYS Fluent to determine hemodynamics.

Computational fluid dynamics modeling {#sec2-3}
-------------------------------------

Blood was modeled as non-Newtonian fluid with a constant density of 1060 kg/m^3^ and shear-dependent dynamic viscosity according to the Carreau model.\[[@ref20]\] The Reynolds number was between 497 and 1132 in the present study, so the blood was assumed to be laminar, incompressible, and could thus be modeled using the Navier--Stokes equations.\[[@ref21]\] Patient-specific systolic peak and end-diastolic velocity of external iliac artery were determined as inflow velocity separately and no slip was prescribed at the stent surface and vessel wall. Zero pressure boundary conditions were prescribed at all outlets, and outflow rates were distributed proportionally according to their cross-sectional area.\[[@ref22]\] Semi-Implicit Method for Pressure Linked Equations algorithm was used as the calculation method.\[[@ref23]\] Second-order upwind was applied to improve the accuracy and stability of the calculation. The iterations were continued until the monitoring points of outlets did not change.

Statistical analysis {#sec2-4}
--------------------

The continuous data were expressed as the median (Q~1~, Q~3~), and Mann--Whitney *U*-test was used for data analysis for the small sample size in this study. The categorical data were expressed as frequency and Fisher\'s exact test was used for comparison. A two-tailed *P* of 0.05 was considered to indicate a statistically significant difference. Statistical analysis was performed with the commercially available SPSS 17.0 software (SPSS Statistics for Windows, Version 17.0. Chicago, USA).

R[esults]{.smallcaps} {#sec1-3}
=====================

Demographic characteristics of patients {#sec2-5}
---------------------------------------

The demographic data of these patients were summarized in [Table 1](#T1){ref-type="table"}. When comparing TRAS group to control group, all demographic data were not statistically different except time to CTA examination after kidney transplantation (4.0 \[3.0, 6.5\] vs. 8.5 \[7.0, 13.0\], *P* = 0.048) \[[Table 2](#T2){ref-type="table"}\].

###### 

Demographics of kidney transplant recipients enrolled in this study

  Patient number   Gender   Age (years)   Height (cm)   Body weight (kg)   AHA   Surgery          Donor type       IST                         Diagnosis (months PT)   Stenosis (%)   CTA after stent
  ---------------- -------- ------------- ------------- ------------------ ----- ---------------- ---------------- --------------------------- ----------------------- -------------- -----------------
  1                Male     29            174           72                 Yes   Single           Deceased         FK + MMF + prednisone       6                       90             Yes
  2                Male     35            166           52                 Yes   Single           Deceased         FK + MMF + prednisone       4                       90             Yes
  3                Female   35            164           48                 Yes   Single           Deceased         FK + MMF + prednisone       5                       90             Yes
  4                Male     50            170           58                 Yes   CPKT             Deceased         CsA + MMF + prednisone      7                       85             Yes
  5                Female   31            163           54                 Yes   Single           Deceased         FK + MMF + prednisone       11                      70             Yes
  6                Male     40            165           50                 Yes   Single           Deceased         FK + MMF + prednisone       4                       70             Yes
  7                Male     35            176           75                 Yes   Single           Deceased         FK + MMF + prednisone       2                       84             No
  8                Male     32            170           68                 Yes   Single           Deceased         CsA + MMF + prednisone      3                       80             No
  9                Male     47            170           72                 Yes   Single           Deceased         CsA + MMF + prednisone      3                       80             No
  10               Male     25            173           68                 Yes   Single           Living related   FK + MMF + prednisone       1                       75             No
  11               Female   16            160           45                 Yes   Single           Living related   FK + MMF + prednisone       9                       70             No
  12               Male     27            170           60                 Yes   Single           Deceased         FK + MMF + prednisone       4                       70             No
  13               Male     29            174           72                 No    Single           Deceased         FK + MMF + prednisone       3                       Control        --
  14               Male     42            172           80                 No    Single           Deceased         FK + MMF + prednisone       24                      Control        --
  15               Male     38            170           56                 No    Autotransplant   Deceased         No                          7                       Control        --
  16               Male     39            172           62                 No    Single           Deceased         FK + MMF + prednisone       13                      Control        --
  17               Female   36            168           53                 No    Single           Living related   CsA + EC−MPS + prednisone   8                       Control        --
  18               Male     40            165           50                 No    Single           Deceased         FK + MMF + prednisone       9                       Control        --

AHA: Antihypertensive agent; CPKT: Combined pancreas--kidney transplantation; IST: Immunosuppressive therapy; FK: FK506; CsA: Cyclosporine A; MMF: Mycophenolate mofetil; EC--MPS: Enteric--coated mycophenolate sodium; PT: Posttransplant; CTA: Computed tomography angiography.

###### 

Comparison of demographics of kidney transplant recipients between TRAS group and control group

  Items                                   TRAS (*n* = 12)        Control (*n* = 6)      Statistics   *P*
  --------------------------------------- ---------------------- ---------------------- ------------ -------
  Gender (male/female)                    9/3                    5/1                    Fisher       1.000
  Age (years)                             33.5 (28.0, 37.5)      38.5 (36.0, 40.0)      −1.315\*     0.188
  Height (cm)                             170.0 (164.5, 171.5)   171.0 (168.0, 172.0)   −0.758\*     0.448
  Weight (kg)                             59.0 (51.0, 70.0)      59.0 (53.0, 72.0)      −0.423\*     0.672
  Donor type (deceased/living--related)   10/2                   5/1                    Fisher       1.000
  Time to CTA examination (months PT)     4.0 (3.0, 6.5)         8.5 (7.0, 13.0)        −1.977\*     0.048
  CNI (FK/CsA/none)                       9/3/0                  4/1/1                  Fisher       0.492
  MPA (MMF/EC--MPS/none)                  12/0/0                 4/1/1                  Fisher       0.098

\**Z* values. PT: Posttransplant; CNI: Calcineurin inhibitor; CTA: Computed tomography angiography; MPA: Mycophenolic acid; MMF: Mycophenolate mofetil; EC--MPS: Enteric--coated mycophenolate sodium; FK: FK506; CsA: Cyclosporine A; TRAS: Transplant renal artery stenosis.

Pressure distribution in normal, stenotic, and stented transplant renal arteries {#sec2-6}
--------------------------------------------------------------------------------

The pressure distribution of TRA is shown in [Figure 1](#F1){ref-type="fig"}. Pressure was uniform in the normal and stented TRA but changed abruptly in the stenotic TRA. In the stenotic TRA, pressure reached to a high level ahead the stenosis, promptly decreased to the trough level at the stenosis throat, and then slightly increased at downstream stenosis leading to an adverse pressure gradient. Similar phenomena were observed at both diastole and systole phases.

![Pressure distribution of normal, stenotic, and stented transplant renal artery. (a) Contours of pressure at end diastole. (b) Contours of pressure at peak systole. Ia: Iliac artery; Tra: Transplant renal artery; Arrows: The direction of blood flow.](CMJ-130-23-g001){#F1}

Velocity in normal, stenotic, and stented transplant renal arteries {#sec2-7}
-------------------------------------------------------------------

Velocity streamline of TRA is shown in [Figure 2](#F2){ref-type="fig"}. The streamlines at the upstream of stenosis were no intersection indicating a laminar flow pattern. However, a mere elliptic-shaped vortex near the inner wall and a separation zone developed at downstream stenosis \[Figure [2a](#F2){ref-type="fig"} and [2c](#F2){ref-type="fig"}\]. The maximal velocity of stenotic TRA significantly increased as compared to normal TRA at both end diastole phase (2.94 \[2.14, 3.30\] m/s vs. 1.06 \[0.89, 1.15\] m/s, *Z* = −3.372, *P* = 0.001) and peak systole phase (3.25 \[2.67, 3.56\] m/s vs. 1.65 \[1.18, 1.72\] m/s, *Z* = −3.373 *P* = 0.001) \[Figure [2b](#F2){ref-type="fig"} and [2d](#F2){ref-type="fig"}\]. As expected, the vortex and separation zone were ameliorated when stent was implanted \[Figure [2a](#F2){ref-type="fig"} and [2c](#F2){ref-type="fig"}\], and the maximal velocity decreased to 0.94 (0.84, 1.02) (*Z* = −3.372, *P* = 0.001) at end diastole phase and 1.24 (1.12, 1.35) m/s (*Z* = −3.373, *P* = 0.001) at peak systole phase \[Figure [2b](#F2){ref-type="fig"} and [2d](#F2){ref-type="fig"}\].

![Velocity of normal, stenotic, and stented transplant renal artery. (a) Contours of velocity streamline at end diastole. (b) Maximal velocity of normal (*n* = 6), stenotic (*n* = 12), and stented (*n* = 6) transplant renal artery at end diastole. (c) Contours of velocity streamline at peak systole. (d) Maximal velocity of normal (*n* = 6), stenotic (*n* = 12), and stented (*n* = 6) transplant renal artery at peak systole. Ia: Iliac artery; Tra: Transplant renal artery; Arrows: The direction of blood flow. Results are the median. \**P* \< 0.05 versus normal; ^†^*P* \< 0.05 versus stenosis.](CMJ-130-23-g002){#F2}

Wall shear stress in normal, stenotic, and stented transplant renal arteries {#sec2-8}
----------------------------------------------------------------------------

Wall shear stress (WSS) is a function of the velocity gradient of blood flow adjacent vascular endothelium, which is proportional to volume flow rate and inversely proportional to the cube of the lumen radius.\[[@ref24]\] The formula is ![](CMJ-130-23-g003.jpg), where τ is the WSS, µ is the blood viscosity, and *r* is lumen radius. The WSS of TRA is shown in [Figure 3](#F3){ref-type="fig"}. A remarkable high WSS was observed mainly at stenosis throat indicated as red zone, and a low WSS was indicated as blue zone at downstream stenosis \[Figure [3a](#F3){ref-type="fig"} and [3e](#F3){ref-type="fig"}\]. Compared to normal TRA, maximal WSS of stenotic TRA significantly increased at both end diastole phase (256.5 \[149.8, 349.4\] Pa vs. 41.7 \[37.8, 45.3\] Pa, *Z* = −3.372, *P* = 0.001) and peak systole phase (281.3 \[184.3, 364.7\] Pa vs. 65.8 (61.2, 71.9) Pa, *Z* = −3.372, *P* = 0.001) \[Figure [3b](#F3){ref-type="fig"} and [3f](#F3){ref-type="fig"}\]. Reversely, minimal WSS of stenotic TRA significantly decreased when compared to normal TRA at both end diastole phase (0.07 \[0.03, 0.13\] Pa vs. 0.52 \[0.45, 0.67\] Pa, *Z* = −3.382, *P* = 0.001) and peak systole phase (0.08 \[0.03, 0.19\] Pa vs. 0.70 \[0.60, 0.81\] Pa, *Z* = −2.952, *P* = 0.001) \[Figure [3d](#F3){ref-type="fig"} and [3h](#F3){ref-type="fig"}\]. The maximal WSS significantly decreased to 118.6 (113.2, 125.1) Pa (*Z* = −2.810, *P* = 0.001) at end diastole phase and 180.3 (163.9, 193.4) Pa (*Z* = −2.154, *P* = 0.001) at peak systole phase after stent implantation \[Figure [3b](#F3){ref-type="fig"} and [3f](#F3){ref-type="fig"}\].

![WSS of normal, stenotic, and stented transplant renal artery. (a) Contours of WSS at end diastole. (b) Maximal WSS of normal (*n* = 6), stenotic (*n* = 12), and stented (*n* = 6) transplant renal artery at end diastole. (c) Average WSS of normal (*n* = 6), stenotic (*n* = 12), and stented (*n* = 6) transplant renal artery at end diastole. (d) Minimal WSS of normal (*n* = 6), stenotic (*n* = 12), and stented (*n* = 6) transplant renal artery at end diastole. (e) Contours of WSS at peak systole. (f) Maximal WSS of normal (*n* = 6), stenotic (*n* = 12), and stented (*n* = 6) transplant renal artery at peak systole. (g) Average WSS of normal (*n* = 6), stenotic (*n* = 12), and stented (*n* = 6) transplant renal artery at peak systole. (h) Minimal WSS of normal (*n* = 6), stenotic (*n* = 12), and stented (*n* = 6) transplant renal artery at peak systole. WSS: Wall shear stress; Ia: Iliac artery; Tra: Transplant renal artery; Arrows: The direction of blood flow. Results are the median. \**P* \< 0.05 versus normal; ^†^*P* \< 0.05 versus stenosis.](CMJ-130-23-g004){#F3}

To accurately compare low WSS region in individual TRAs, the low-WSS region ratio (area~low\ WSS~/area~total~) was introduced to neutralize the variation of vascular or stent area. Area~low~ WSS referred to dark blue zone and area total meant target vascular or stent area, as shown in Figure [4a](#F4){ref-type="fig"} and [4c](#F4){ref-type="fig"}. When compared to normal TRA, low-WSS region ratio significantly increased in stenotic TRA at end diastole phase (0.84 \[0.72, 0.93\] vs. 0.14 \[0.11, 0.16\], *Z* = −3.380, *P* = 0.001) or at peak systole phase (0.81 \[0.74, 0.91\] vs. 0.14 \[0.13, 0.15\], *Z* = −3.379, *P* = 0.001) \[Figure [4b](#F4){ref-type="fig"} and [4d](#F4){ref-type="fig"}\]. Notably, low-WSS region ratio did not decrease after stenting either at end diastole phase (0.84 \[0.78, 0.91\], *Z* = −0.423, *P* = 0.672) or at peak systole phase (0.84 \[0.78, 0.90\], *Z* = −0.469, *P* = 0.639) \[Figure [4b](#F4){ref-type="fig"} and [4d](#F4){ref-type="fig"}\].

![WSS distribution of the stented segment of transplant renal artery and low WSS ratio (area low WSS/area total) of normal, stenotic, and stented transplant renal artery. A large area of low WSS (dark blue zone) was clearly visible around the stent struts and high WSS (red zone) was just at the stent struts. (a) WSS distribution at end diastole. (b) Low WSS ratio (area low WSS/area total) at end diastole. (c) WSS distribution at peak systole. (d) Low WSS ratio at peak systole. WSS: Wall shear stress; Arrows: The direction of blood flow. Results are the median. \**P* \< 0.05 versus normal.](CMJ-130-23-g005){#F4}

Mass flow rate in normal, stenotic, and stented transplant renal arteries {#sec2-9}
-------------------------------------------------------------------------

Mass flow rate (MFR) of TRA represents blood flow into renal grafts per unit time. The MFR of TRA is shown in [Figure 5](#F5){ref-type="fig"}. Compared to normal TRA, MFR of stenotic TRA significantly decreased at either end diastole phase (1.5 \[1.0, 3.0\] g/s vs. 11.0 \[8.0, 11.3\] g/s, *Z* = −3.420, *P* = 0.001) or peak systole phase (2.0 \[1.3, 3.3\] g/s vs. 16.5 \[13.0, 20.3\] g/s, *Z* = −3.395, *P* = 0.001) \[Figure [5a](#F5){ref-type="fig"} and [5c](#F5){ref-type="fig"}\]. When stent was implanted, MFR increased to 8.0 (6.0, 15.5) g/s (*Z* = −3.414, *P* = 0.001) at end diastole and 10.0 (9.5, 21.0) g/s (*Z* = −3.356, *P* = 0.001) at peak systole \[Figure [5a](#F5){ref-type="fig"} and [5c](#F5){ref-type="fig"}\]. To accurately evaluate blood flow distribution in individual TRAs, MFR ratio (MFR~outlet~/MFR~inlet~) was introduced to neutralize the variation of individuals. The proximal end of iliac artery was defined as the inlet, and the TRA and distal end of iliac artery were defined as the outlets in the present study. Hence, TRA MFR ratio could be expressed as MFR~TRA~/MFR~inlet.~ When compared to normal TRA, TRA MFR ratio significantly decreased in stenotic TRA at end diastole phase (0.03 \[0.02, 0.05\] vs. 0.19 \[0.15, 0.25\], *Z* = −3.375, *P* = 0.001) or at peak systole phase (0.04 \[0.02, 0.05\] vs. 0.20 \[0.18, 0.25\], *Z* = −3.375, *P* = 0.001) \[Figure [5b](#F5){ref-type="fig"} and [5d](#F5){ref-type="fig"}\]. The TRA MFR ratio significantly increased to 0.19 (0.17, 0.21) (*Z* = −3.375, *P* = 0.001) at end diastole phase and 0.20 (0.18, 0.21) (*Z* = −3.373, *P* = 0.001) at peak systole phase after stent implantation \[Figure [5b](#F5){ref-type="fig"} and [5d](#F5){ref-type="fig"}\].

![MFR and MFR ratio in normal (*n* = 6), stenotic (*n* = 12), and stented (*n* = 5) transplant renal artery. (a) MFR of diastole. (b) MFR ratio (MFR TRA/MFR inlet) of diastole. (c) MFR of systole. (d) MFR ratio (MFR TRA/MFR inlet) of systole. MFR: Mass flow rate; TRA: Transplant renal artery. Results are the median. \**P* \< 0.05 versus normal; ^†^*P* \< 0.05 versus stenosis.](CMJ-130-23-g006){#F5}

D[iscussion]{.smallcaps} {#sec1-4}
========================

This study demonstrated the hemodynamic characteristics of TRAS and its alteration after stent treatment using a patient-specific CFD model. Maximal velocity increased by 2 times, maximal WSS increased by 4--6 times, and MFR decreased by 80% when comparing TRAS to normal TRA. Stent implantation restored or ameliorated the alterations of the above hemodynamic factors. Low-WSS region ratio significantly increased in TRAS by 8 times and remained unchanged after stent implantation.

As observed, pressure significantly dropped across stenosis throat and produced an adverse pressure gradient, which is prone to destabilize the blood flow. Meanwhile, retardation of flow velocity led to a separation of adjacent vessel blood from the inner mainstream, and thus caused the formation of downstream separation zone. The separation zone is considered to be harmful since it may prolong the resident time of blood at poststenosis area. A remarkable increased WSS at stenosis throat was observed. It is of note that the maximum WSS was approximately 412 Pa and 370 Pa at peak systole and end diastole phase, respectively, which is much higher than the published data in artery stenosis.\[[@ref22][@ref24]\] According to the formula of WSS, changes in lumen radius might result in significant changes of WSS. Hence, one possible explanation for our results is the significantly narrow lumen radius in the present study. The degree of all stenosis enrolled in this study was over 70% and even up to 90% in some TRAS.

Large low WSS area was observed at the downstream of stenosis in this study. The large low WSS area may accelerate stenosis progression or lead to secondary stenosis unless timely treatment is implemented. It is reported that distal region of stenotic artery is more prone to develop atherosclerosis.\[[@ref25]\] Multiple stenosis usually occurred at the downstream of a diseased vascular bed due to low WSS area distal to the primary stenosis.\[[@ref26]\] The possible mechanism is that low WSS can influence the development of neointimal hyperplasia and lead to stenosis by triggering inflammatory cell-mediated destructive remodeling.\[[@ref27][@ref28]\] MFR dramatically decreased in stenotic TRA, which is in accordance with the finding that MFR appeared with apparent reduction when stenosis degree was over 50%.\[[@ref12]\]

It is not surprising to find that hemodynamics of TRAS was significantly improved by stent implantation in the aspects of uniform pressure distribution, ameliorated vortex and separation zone, corrected abnormal velocity, decreased maximal WSS, and increased MFR. However, it is of note that large low WSS area was found at stent region, and low-WSS region ratio remained unchanged after stent implantation. This is in accordance with findings from published studies on stented coronary and vertebral arteries.\[[@ref9][@ref29]\] The influence of stent on geometry of vessel wall has not been fully understood. Nevertheless, alteration in cross-sectional geometry after stent implantation exerts an important impact on WSS distributions, which may play roles in subsequent restenosis.\[[@ref30]\] Low WSS is reported to be related to endothelial cell proliferation and formation of in-stent neointima.\[[@ref31]\]

Our study has several limitations that deserve to mention. First, although CFD can provide clinically relevant hemodynamic information, more clinical studies and analyses should be carried out to prove the accuracy and validity. Second, the basis of CFD methodology is governed by the transient Navier--Stokes equations with the fluid assumed as an incompressible non-Newtonian, laminar fluid. The effect of artery compliance and blood flow waveform was not considered in the present study. The biological response of the vascular wall was not considered here, and merely hemodynamic effects were investigated.

In conclusion, our study revealed that the hemodynamics including pressure distribution, velocity, WSS, and MFR changed significantly when TRAS occurred by CFD based on a patient-specific model. Moreover, stent implantation may leave an intrinsic risk factor for restenosis of TRAS. Further studies are needed to determine its effect on clinical outcome.
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